INTRODUCTION
The discovery of the cannabinoid receptors, CB 1 (Matsuda et al 1990) and CB 2 (Munro et al 1993) represents a significant milestone in cannabinoid research. CB 1 is the central receptor found in brain and neuronal cells and mediates such physiological responses as analgesia and catalepsy. The peripheral receptor, CB 2 , is primarily expressed in spleen and immune cells. The role of CB 2 in mediating physiological effects has not been fully determined, but it is believed that CB 2 may be involved in cannabinoid-mediated immune responses (Bouaboula et al 1998 , Portier et al 1999 . A large variety of compounds have been found to bind to the receptors, including natural and synthetic cannabinoids (Razdan 1986 , Keimowitz et al 2000 , aminoalkylindoles (Bell et al 1991 , Shim et al 1998 , endogenous ligands, and diarylpyrazoles (Compton et al 1996 , Wiley et al 2001 .
The first synthetic compound reported to have antagonist/inverse agonist properties toward the cannabinoid receptor is SR141716A (Rinaldi-Carmona et al 1994) , a diarylpyrazole analogue (Figure 1 ). SR141716A exhibits strong (low nanomolar) affinity for CB 1 but rather low affinity (approaching micromolar) for CB 2 (Rinaldi-Carmona et al 1994 , Showalter et al 1996 , Felder et al 1995 . Two less potent CB 1 selective analogues, AM251 and AM281 (Figure 1 ) have also been reported (Gatly et al 1997 , Lan et al 1999 , Cosenza et al 2000 .
It is believed that the antagonistic activity of the diarylpyrazoles is attributable to the structural properties of 1-and 5-substituents whereas the 3-substituent appears to be involved in agonism and receptor activation (Wiley et al 2001) . Thus, even small modifications on the 1-and 5-substituents result in decreased affinity and loss of antagonism, indicating the essential role of the area in conferring receptor recognition and antagonist activity to the diarylpyrazole compounds. On the other hand, replacement of the 3-substituent of the pyrazole ring with This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 22, 2004 as DOI: 10.1124 at ASPET Journals on April 28, 2017 dmd.aspetjournals.org Downloaded from functional groups such as ethers and alkyl amides generally leads to dramatic decreases in CB 1 binding affinities (Lan et al 1999) . For 3-substituent analogs that show significant receptor affinity, partial agonist properties have been observed (Wiley et al 2001) .
Structural modifications to the diarylpyrazoles as a result of metabolism, however, have not been reported. In light of the sensitivity of the receptor recognition and antagonistic efficacy of diarylpyrazoles to structural variations on the 1-, 3-, and 5-subtituents (Figure 1) , it can be hypothesized that potential metabolites of these ligands may lose much of their receptor binding affinity and/or antagonist properties. It is also possible that some of the metabolic products may retain a significant amount of antagonism of the parent compounds if structural modifications occur at less crucial sites. Thus, knowledge of the metabolic transformation of the diarylpyrazoles is required to evaluate the role of metabolites in the overall efficacy of the antagonists. The current study investigates the in vitro metabolism of SR141716A, AM251, and AM281 using rat liver microsomes. High performance liquid chromatography (HPLC) was used for the separation of complex metabolic mixtures, and tandem mass spectrometry (MS/MS) along with high-resolution nuclear magnetic resonance (NMR) spectroscopy techniques were employed in the structural elucidation of various metabolic products of the diarylpyrazole analogs. Synthesis of SR141716A Synthesis of SR141716A was carried out following procedures reported by Dutta et al (1994) . Briefly, bromination of 4-chloropropiophenone gave the bromoketone intermediate. Treatment of the anion of ethyl acetoacetate with the bromoketone furnished the acetoacetate derivative. The sodium salt of the acetoacetate derivative was allowed to react with a solution of 2,4-dichlorodiazonium chloride, followed by base hydrolysis to give the pyrazole carboxylic acid which was then treated with 1-aminopiperidine and triethylamine to give the target compound. The product was purified by flash chromatography and crystallized from methanol. Structural confirmation of the synthetic SR141716A was done by 1 H and 13 C NMR spectroscopy (Tables 1-3 ) and HPLC-MS/MS (Figure 2 ).
Microsomal Incubations Stock solutions of SR141716A, AM-251, and AM-281 were prepared in DMSO, at a concentration of 20 mM. Rat liver microsomes containing 1.8 mg/ml of protein were pre-incubated at 37 °C for 3 minutes. The 0.2-mL incubation aliquots contained 75 mM potassium phosphate (pH 7.4), 17 mM magnesium chloride, 7 mM NADP + , 17 mM glucose-6-phosphate, and 1.2 units/mL of glucose-6-phosphate dehydrogenase. To the incubation aliquots were added 1 µL of the SR141716A, AM281, or AM251 stock solution. Incubation times ranged from 0.5 to 2 hours. Incubations were halted by placing the vials in an ice bath followed by adding an equal volume of methanol (0.2 mL). The quenched incubation mixtures were stored at -20°C until analysis. Prior to HPLC separation, microsomal proteins were precipitated by centrifugation (10,000g, 15 min) at room temperature, and the supernatant was evaporated with a stream of nitrogen at 37 °C to 0.2 mL. The residual solution was applied to 6-ml SUPELCO (Bellefonte, PA) C 18 solid-phase extraction columns pretreated with water (4 x 4
This article has not been copyedited and formatted. The final version may differ from this version. mL) and methanol (4 x 4 mL). The columns were washed with HPLC-grade water (2 x 3 mL) and eluted with methanol (3 x 3 mL); the effluents were again concentrated by a nitrogen stream at 37°C to 1.0 mL. For semipreparative purposes, a total of 5x10mL larger scale incubations were carried out. In each 10-mL incubation mixture were 18 mg protein, 75 mM potassium phosphate buffer (pH 7.4), 17 mM magnesium chloride, 7 mM NADP + , 17 mM glucose-6-phosphate, and 1.2 units/mL of glucose-6-phosphate dehydrogenase and 50 µL of 20mM SR141716A.
Control incubations were performed under identical conditions with heat-inactivated microsomes (heated to 100°C for 10 min). In addition, incubations in the absence of NADPH, or in the absence of microsomes, were carried out. To eliminate matrix interferences arising from microsomes and buffer components, blank incubations were done where all elements were present except the drug compounds. 
HPLC-UV Analysis

RESULTS
SR141716A (a)
Detailed LC-MS/MS and NMR spectroscopic analysis of the parent compound SR141716A (a) were carried out to facilitate identification of the structures of its metabolites.
The full scan mass spectrum of a showed a prominent protonated molecule ( Table 2 ). The 13 C NMR chemical shifts of SR141716A are presented in Table 3 . The 13 C NMR assignments were assisted by DPET, HMQC and HMBC.
The broad single peak at around δ 7.60 ( 1 H) can be assigned to the NH-proton at W. Clearly, the four protons at δ 2.86 are the two CH 2 groups (A and E) next to the nitrogen atom, the two protons at δ 1.40 belong to the CH 2 (D), and the other four at δ 1.75 are the two CH 2 groups (B and C).
SR141716A Metabolites
Shown in Figure 3 are the total ion chromatogram (TIC) obtained from an incubation product mixture and the selected ion chromatograms for m/z 477, 479, and 461 that were extracted from a single run. The selected ion chromatogram for m/z 477 is shown in Figure 3A ,
in which 2 peaks are observed at retention times of 17.63 min. and 18.25 min., respectively. and Ma2 are identical and the spectrum is shown in Figure 4 . A comparison with the product ion spectrum of SR141716A and its proposed fragmentation pathways (Figure 2) indicates that the fragment ion at m/z 98 is related to the SR141716A fragment ion at m/z 84. All other identical fragment ions provide evidence that the only site of metabolic oxidation occurring in Ma1 and
Ma2 is the piperidine moiety. The proposed fragmentation pathways are also given in Figure 4 based on the tandem mass spectral details. piperidine ring is therefore the site of oxidation. Four possible structures can be envisioned, the tertiary N-oxide (i), or a hydroxylated structure (ii, iii, iv), as illustrated in Chart 1.
The tertiary N-oxide i would be expected to have 10 proton signals in the piperidine ring.
In the 1 H NMR spectrum of Ma4, only 9 proton signals were observed in this region (Table 1) Overall, the NMR data points to the fourth structure (iv) as the structure of Ma4 with 
AM251 (b)
The product ion spectrum of AM251 (b) was obtained before HPLC-MS/MS analysis of the incubation products. All tandem mass spectral data for AM251 and its metabolites are summarized in Table 4 . The total ion chromatogram of an incubation product mixture and the selected ion chromatograms for the metabolites are shown in Figure 7 . The selected ion chromatogram for m/z 571 in Figure 7A shows two peaks (Mb1 and Mb2) at retention times of indicates an increase of 16 mass units compared to the parent compound AM251, consistent with the addition of a single oxygen atom to the structure. The tandem mass spectra data (Table 4) show that Mb1 and Mb2 both share several identical fragment ions with AM251, i.e., Fb1 to Fb4 at m/z 455, 391, 328, 374, and 256, indicating no metabolic modification on these fragments.
The two fragment ions, Fb5 and Fb6, are each at 16 mass units higher than their counterparts of the parent compound AM251. This information indicates that the piperidine ring of AM251 has been hydroxylated. The fragmentation of the ion at m/z 100 via a dehydration pathway is responsible for the ion observed at m/z 82, suggesting the involvement of a hydroxyl group on the dihydropiperidine moiety. 
Mb3 and
AM281 (c)
The full scan mass spectrum of the parent compound showed a prominent protonated peak at m/z 557 Da., which upon CID results in a product ion at m/z 455 ( Table 5) (Figure 9) , which upon dehydration leads to Ma1 and Ma2.
In AM251 the p-chlorophenyl group is replaced by a p-iodophenyl substituent, which is the only structural difference between it and SR141716A. It appears that such a structural difference may be responsible for the observation of only four metabolites for AM251 (Figure   10 ), compared to six total for SR141716A. The metabolic pathways of AM251 involving In conclusion, it has been demonstrated that three diarylpyrazole analogues that behave as, cannibinoid receptor antagonists, undergo unique metabolic pathways that are shared neither by traditional cannabinoids nor by synthetic agonists such as aminoalkylindoles (AAIs). Unlike
AAIs where extensive hydroxylations were observed at various sites of the parent compounds (Zhang et al 2002 (Zhang et al , 2004 , the only site vulnerable to metabolic activities appears to be the terminal group of the 3-substituent on the pyrazole ring (Figure 1) , whereas no metabolic modification has been detected at other sites of the diarylpyrazoles. Given the sensitivity of antagonist properties to structural variations on the 3-substituent (Wiley et al 2001 , Lan et al 1999 , it will be of great interest to understand whether the metabolites still bind to the receptors with considerable affinity, and furthermore, whether they behave as antagonists or agonists after structural modifications on the 3-substituents. With one major metabolite of SR141716A (Ma1) isolated in pure form, further studies are now possible to determine the receptor binding affinities and physiological efficacies of the metabolite for both CB 1 and CB 2 .
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